NotesFAQContact Us
Collection
Advanced
Search Tips
Showing all 4 results Save | Export
Peer reviewed Peer reviewed
Direct linkDirect link
Serdar Karatoprak; Sadettin Burak Acikel; Abdulbaki Akyildiz; Fatma Coskun; Fatma Hümeyra Yerlikaya – International Journal of Developmental Disabilities, 2024
Background: Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder, the etiology of which has not been clearly determined yet. There is increasing evidence that synaptic and dendritic changes are involved in the etiology of ASD. The aim of this study is to determine whether serum Thrombospondin-1 and Thrombospondin-2 differ between ASD…
Descriptors: Children, Autism Spectrum Disorders, Etiology, Metabolism
Peer reviewed Peer reviewed
Direct linkDirect link
Erickson, Craig A.; Wink, Logan K.; Early, Maureen C.; Stiegelmeyer, Elizabeth; Mathieu-Frasier, Lauren; Patrick, Vanessa; McDougle, Christopher J. – Journal of Autism and Developmental Disorders, 2014
Rationale: An excitatory/inhibitory (E:I) imbalance marked by enhanced glutamate and deficient gamma-aminobutyric acid (GABA) neurotransmission may contribute to the pathophysiology of autism spectrum disorders (ASD). Objectives: We report on the first single-blind placebo lead-in trial of acamprosate, a drug with putative mechanisms restoring E:I…
Descriptors: Autism, Pervasive Developmental Disorders, Drug Therapy, Metabolism
Peer reviewed Peer reviewed
Direct linkDirect link
Aman, Michael G.; Hollway, Jill A.; Leone, Sarah; Masty, Jessica; Lindsay, Ronald; Nash, Patricia; Arnold, L. Eugene – Research in Developmental Disabilities: A Multidisciplinary Journal, 2009
This study was designed to explore the placebo-controlled effects of risperidone on cognitive-motor processes, dyskinetic movements, and behavior in children receiving maintenance risperidone therapy. Sixteen children aged 4-14 years with disruptive behavior were randomly assigned to drug order in a crossover study of risperidone and placebo for 2…
Descriptors: Metabolism, Behavior Problems, Reaction Time, Hyperactivity
Peer reviewed Peer reviewed
Direct linkDirect link
Handen, Benjamin L.; Hardan, Antonio Y. – Journal of the American Academy of Child & Adolescent Psychiatry, 2006
Objective: Olanzapine, an atypical antipsychotic, has been shown to be efficacious for treatment of psychotic and mood disorders in adults. This prospective, open-label study was conducted to examine the safety and usefulness of olanzapine in treating disruptive behavior disorders in adolescents with subaverage intelligence. Method: Sixteen…
Descriptors: Check Lists, Intelligence, Safety, Moderate Mental Retardation